# Alexandra Gylfe

> Alexandra Gylfe is a seed investor at Nordic Science Investments backing Medical and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Nordic Science Investments](https://shizune.co/investors/profile/nordic-science-investments)
- Location: Helsinki, Finland
- Total investments: 5
- Last investment: Jun 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/agylfe
- X (Twitter): https://twitter.com/AlexandraG29436
- Facebook: https://www.facebook.com/agylfe

Alexandra Gylfe is a seed investor at Nordic Science Investments in Helsinki focused on Medical and Health Care. Alexandra Gylfe is the Founder of Nordic Science Investments. She previously worked at Helsinki Innovation Services as a Business Development Director. Alexandra Gylfe attended Aalto University Executive Education and Professional Development.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 40% |
| Health Care | 2 | 40% |
| Biotechnology | 2 | 40% |
| Health Diagnostics | 2 | 40% |
| SaaS | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 60% |
| Pre-Seed | 1 | 20% |
| Series A | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Finland | 4 | 80% |
| Sweden | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AIATELLA | AIATELLA transforms cardiovascular diagnostics by harnessing AI to automate quantification, detection, and interpretation of medical images across multiple imaging modalities. Their technology boosts efficiency, ensures standardized analysis, and enables precision medicine, addressing the global challenges of radiologist shortages and the risingburden of cardiovascular diseases. | $2.3M | Seed | Jun 04, 2025 |  |
| RNatives | RNatives specializes in the field of biotechnology, focusing on the development of innovative RNA-based therapies. The company's expertise lies in RNA activation, particularly targeting VEGFA for the treatment of cardiovascular diseases. RNatives is dedicated to advancing its lead programs through rigorous research and development, aiming tooffer novel therapeutic options for conditions with unmet medical needs. With a team of skilled professionals, RNatives is committed to pushing the boundaries of biotechnology to improve patient outcomes. | $1.6M | Seed | May 27, 2025 |  |
| SampleFacts | Next generation Dried Blood Spot sampling – separating cells and plasma at the point of collection. | $1.8M | Seed | May 09, 2025 |  |
| Solid IO | Solid IO believes cancer care should be as precise and personal as possible. Solid IO’s tumor-on-chip platform is transforming oncology, delivering real-time, patient-specific insights that empower clinicians to make life-changing treatment decisions. With Solid IO, the next era of precision oncology | $836.9K | Pre-Seed | Feb 24, 2025 |  |
| NADMED | The NADMED test was developed by one of the world's foremost experts on NAD metabolism in humans. NADMED's metabolite extraction system is the only method for measuring all four NADs and glutathione. | $3.9M | Series A | Aug 22, 2024 |  |

5 of 5 investments shown.

## Co-investors
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund, 2 deals together
- [University of Helsinki](https://shizune.co/investors/profile/university-of-helsinki) — VC Fund, 2 deals together
- [BSV Ventures](https://shizune.co/investors/profile/baltic-sandbox-ventures) — VC Fund, 1 deal together
- [CVX Ventures](https://shizune.co/investors/profile/cvx-ventures) — VC Fund, 1 deal together
- [Force 10 Partners](https://shizune.co/investors/profile/force-10-partners) — VC Fund, 1 deal together
- [Harjavalta Oy](https://shizune.co/investors/profile/harjavalta-oy) — VC Fund, 1 deal together

## About Nordic Science Investments

VC Fund

Nordic Science Investments is a capital investment fund.

3 contacts available at Nordic Science Investments.

| Name | Title | Profile |
| --- | --- | --- |
| Alexandra Gylfe | Founding Partner | https://shizune.co/investors/profile/alexandra-gylfe |
| Matti Hautsalo | Founding Partner | https://shizune.co/investors/profile/matti-hautsalo |
| Mart Maasik | Partner | https://shizune.co/investors/profile/mart-maasik |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Alexandra Gylfe invest in?

Alexandra Gylfe invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 5 investments tracked by Shizune back companies in Finland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alexandra Gylfe last invest?

The most recent investment recorded for Alexandra Gylfe closed in Jun 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co